The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma

The ubiquitin-proteasome signaling pathway is critical for cell cycle regulation and neoplastic growth. Proteasome inhibition can activate apoptotic pathways. Bortezomib, a selective proteasome inhibitor, has anti-melanoma activity. MLN2238 (ixazomib), an oral proteasome inhibitor, has improved phar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Suarez, Lorena P., Kemper, Gregory M., Duggan, Megan C., Stiff, Andrew, Noel, Tiffany C., Markowitz, Joseph, Luedke, Eric A., Yildiz, Vedat O., Yu, Lianbo, Jaime-Ramirez, Alena Cristina, Karpa, Volodymyr, Zhang, Xiaoli, Carson, William E.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5348384/
https://ncbi.nlm.nih.gov/pubmed/27783987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados